跳至主要内容
临床试验/NCT02285335
NCT02285335Unknown不适用

Effects of GINST on Human Semen

Yonsei University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2014年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
Semen quality (assessed by computer aided semen analysis and sperm chromatin assay, malondialdehyde (MDA) analysis)

研究概览

简要总结

The purpose of the study is to evaluate the effect of GINST on human semen. The study is a pilot study, designed as open-label, prospective randomized clinical trial using GINST either 500mg/capsule (panax ginseng 0.96g/day) or 1000mg/capsule (panax ginseng 1.92g/day), two capsules at once, three times a day for 12 weeks. GINST(Ilhwa, Republic of Korea) is a dietary supplement capsule, which is made with 6 year-old Korean red ginseng (Panax ginseng). Expected participants are to be male partners of female patients who visit infertility clinic at Severance hospital, whose total motile sperm count is more than 0.5x106 by semen analysis using computer aided sperm analyzer (CASA). Semen analysis, blood test, questionaires are planned to be performed 2 times, on the initial visit and after 12weeks of GINST treatment. Semen analysis will reveal ejaculated volume, sperm count, motility, morphology, total leukocyte count, total motile sperm count, further analysis including sperm chromatin assessment to examine the quality of sperm and malondialdehyde (MDA) analysis of seminal fluid to assess oxidative stress will be performed. Blood test will be done including serum follicle stimulating hormone (FSH), luteinizing hormone (LH), total and free testosterone. Quality of life, sexual performance before and after taking GINST will be evaluated using questionaires.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •partner of female patient who visit infertility clinic with chief complaint of infertility.
  • •≥0.5x106 of total motile sperm count on screening semen analysis.

排除标准

  • •Those who have chronic, systemic disease or endocrinologic disorder.
  • •Patients with hypertension (systolic blood pressure ≥ 140mmHg, diastolic blood pressure ≥ 90mmHg)
  • •Patients who have undergone chemotherapy due to malignancy
  • •Patient who has history of taking testosterone or anti androgen agents within 1 month.
  • •Patient who has retrieved sperm surgically

研究组 & 干预措施

Low group

Experimental

GINST15 3g/day

干预措施: GINST (Dietary Supplement)

High group

Experimental

GINST15 6g/day

干预措施: GINST (Dietary Supplement)

结局指标

主要结局

Semen quality (assessed by computer aided semen analysis and sperm chromatin assay, malondialdehyde (MDA) analysis)

时间窗: 12 week

Semen quality assessed by computer aided semen analysis and sperm chromatin assay, malondialdehyde (MDA) analysis

次要结局

  • Quality of Life (SF-36, Brief sexual function inventory, fatigue severity scale)(12 week)
  • serum hormones (serum FSH(follicle stimulating hormone), LH(luteinizing hormone), testosterone)(12 week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验